Gastritis classification: Difference between revisions
No edit summary |
No edit summary |
||
Line 15: | Line 15: | ||
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Gastritis synonyms | ! style="background:#4479BA; color: #FFFFFF;" align="center" + |Gastritis synonyms | ||
|- | |- | ||
| colspan="2" style="background:#DCDCDC;" align="center" + | Non-atrophic | | colspan="2" style="background:#DCDCDC;" align="center" + | '''Non-atrophic''' | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
*''[[Helicobacter pylori]]'' | *''[[Helicobacter pylori]]'' | ||
Line 27: | Line 27: | ||
*Type B* | *Type B* | ||
|- | |- | ||
| rowspan="4" style="background:#DCDCDC;" align="center" + |Atrophic | | rowspan="4" style="background:#DCDCDC;" align="center" + |'''Atrophic''' | ||
| style="background:#DCDCDC;" align="center" + |Autoimmune | | style="background:#DCDCDC;" align="center" + |'''Autoimmune''' | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
*[[Autoimmunity]] | *[[Autoimmunity]] | ||
Line 36: | Line 36: | ||
*[[Pernicious anemia]]-associated | *[[Pernicious anemia]]-associated | ||
|- | |- | ||
| rowspan="3" style="background:#DCDCDC;" align="center" + |Multifocal atrophic | | rowspan="3" style="background:#DCDCDC;" align="center" + |'''Multifocal atrophic''' | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
*''[[Helicobacter pylori]]'' | *''[[Helicobacter pylori]]'' | ||
Line 52: | Line 52: | ||
*Metaplastic | *Metaplastic | ||
|- | |- | ||
| rowspan="21" style="background:#DCDCDC;" align="center" + | Special forms | | rowspan="21" style="background:#DCDCDC;" align="center" + | '''Special forms''' | ||
| rowspan="4" style="background:#DCDCDC;" align="center" + | Chemical | | rowspan="4" style="background:#DCDCDC;" align="center" + | '''Chemical''' | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
*Chemical irritation | *Chemical irritation | ||
Line 74: | Line 74: | ||
*Type C | *Type C | ||
|- | |- | ||
| style="background:#DCDCDC;" align="center" + |Radiation | | style="background:#DCDCDC;" align="center" + |'''Radiation''' | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
*[[Radiation injury]] | *[[Radiation injury]] | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
|- | |- | ||
| rowspan="4" style="background:#DCDCDC;" align="center" + |Lymphocytic | | rowspan="4" style="background:#DCDCDC;" align="center" + |'''Lymphocytic''' | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
*Idiopathic? [[Immune]] mechanisms | *Idiopathic? [[Immune]] mechanisms | ||
Line 98: | Line 98: | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
|- | |- | ||
| rowspan="5" style="background:#DCDCDC;" align="center" + |Noninfectious granulomatous | | rowspan="5" style="background:#DCDCDC;" align="center" + |'''Noninfectious granulomatous''' | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
*[[Crohn's disease]] | *[[Crohn's disease]] | ||
Line 120: | Line 120: | ||
*Isolated [[granulomatous]] | *Isolated [[granulomatous]] | ||
|- | |- | ||
| rowspan="2" style="background:#DCDCDC;" align="center" + |Eosinophilic | | rowspan="2" style="background:#DCDCDC;" align="center" + |'''Eosinophilic''' | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
*[[Food allergy|Food sensitivity]] | *[[Food allergy|Food sensitivity]] | ||
Line 130: | Line 130: | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
|- | |- | ||
| rowspan="2" style="background:#DCDCDC;" align="center" + |Other infectious gastritides | | rowspan="2" style="background:#DCDCDC;" align="center" + |'''Other infectious gastritides''' | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
*[[Bacteria]] (other than ''[[Helicobacter pylori]]'') | *[[Bacteria]] (other than ''[[Helicobacter pylori]]'') | ||
Line 204: | Line 204: | ||
! colspan="1" rowspan="1" style="background:#4479BA; color: #FFFFFF;" + | Grading guidelines | ! colspan="1" rowspan="1" style="background:#4479BA; color: #FFFFFF;" + | Grading guidelines | ||
|- | |- | ||
| style="background:#DCDCDC; + " | Chronic inflammation | | style="background:#DCDCDC; + " | '''Chronic inflammation''' | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
*Increased [[lymphocytes]] and [[plasma cells]] in [[lamina propria]] | *Increased [[lymphocytes]] and [[plasma cells]] in [[lamina propria]] | ||
Line 210: | Line 210: | ||
* Mild, moderate or severe increase in density | * Mild, moderate or severe increase in density | ||
|- | |- | ||
| style="background:#DCDCDC; + " | Activity | | style="background:#DCDCDC; + " | '''Activity''' | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
*[[Neutrophil|Neutrophilic]] infiltrates of the [[lamina propria]], pits or surface [[epithelium]] | *[[Neutrophil|Neutrophilic]] infiltrates of the [[lamina propria]], pits or surface [[epithelium]] | ||
Line 218: | Line 218: | ||
* Severe: more than two-thirds | * Severe: more than two-thirds | ||
|- | |- | ||
| style="background:#DCDCDC; + " | [[Atrophy]] | | style="background:#DCDCDC; + " | [[Atrophy|'''Atrophy''']] | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
*Loss of specialized glands from either [[antrum]] or corpus | *Loss of specialized glands from either [[antrum]] or corpus | ||
Line 224: | Line 224: | ||
* Mild, moderate, or severe loss | * Mild, moderate, or severe loss | ||
|- | |- | ||
| style="background:#DCDCDC; + " | ''[[Helicobacter pylori]]'' | | style="background:#DCDCDC; + " | ''[[Helicobacter pylori|'''Helicobacter pylori''']]'' | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
*''[[H. pylori]]'' density | *''[[H. pylori]]'' density | ||
Line 232: | Line 232: | ||
* Severe colonization: large clusters or a continuous layer over two-thirds of surface | * Severe colonization: large clusters or a continuous layer over two-thirds of surface | ||
|- | |- | ||
| style="background:#DCDCDC; + " | Intestinal [[Metaplasia]] | | style="background:#DCDCDC; + " | '''Intestinal [[Metaplasia]]''' | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
*[[Intestinal]] [[metaplasia]] of the epithelium | *[[Intestinal]] [[metaplasia]] of the epithelium |
Revision as of 15:45, 28 December 2017
Gastritis Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Gastritis classification On the Web |
American Roentgen Ray Society Images of Gastritis classification |
Risk calculators and risk factors for Gastritis classification |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aravind Reddy Kothagadi M.B.B.S[2]}}
Overview
The Updated Sydney System establishes the classification and grading of gastritis which underlines the significance of combining topographical, morphological, and etiological information to help arrive at clinical diagnosis. In clinical practice, gastritis staging is done using the OLGA (Operative Link on Gastritis Assessment) staging system for reporting gastric histology. Gastritis staging combines the atrophy score which is determined by biopsy and the atrophy topography which is determined by directed biopsy mapping.
Classification
- The Updated Sydney System establishes the classification and grading of gastritis which underlines the significance of combining topographical, morphological, and etiological information to help arrive at clinical diagnosis. [1]
Classification and grading of Gastritis: Updated Sydney System | |||
---|---|---|---|
Type of Gastritis | Etiology | Gastritis synonyms | |
Non-atrophic |
|
| |
Atrophic | Autoimmune |
| |
Multifocal atrophic |
| ||
|
| ||
|
| ||
Special forms | Chemical |
|
|
| |||
|
| ||
Radiation | |||
Lymphocytic |
|
| |
| |||
|
|||
Noninfectious granulomatous | |||
|
|||
|
|||
|
| ||
Eosinophilic | |||
|
|||
Other infectious gastritides |
|
| |
- In clinical practice, Gastritis staging is done using the OLGA (Operative Link on Gastritis Assessment) staging system for reporting gastric histology. Gastritis staging combines the atrophy score which is determined by biopsy and the atrophy topography which is determined by directed biopsy mapping. [2] [3]
Gastritis staging in clinical practice: The OLGA staging system | |||||
---|---|---|---|---|---|
Atrophy Score | Corpus | ||||
No Atrophy (Score: 0) | Mild Atrophy (Score: 1) | Moderate Atrophy (Score: 2) | Severe Atrophy (Score: 3) | ||
A N T R U M |
No Atrophy (Score: 0) (including incisura angularis) | STAGE 0 | STAGE I | STAGE II | STAGE II |
Mild Atrophy (Score: 1) (including incisura angularis) | STAGE I | STAGE I | STAGE II | STAGE III | |
Moderate Atrophy (Score: 2) (including incisura angularis) | STAGE II | STAGE II | STAGE III | STAGE IV | |
Severe Atrophy (Score: 3) (including incisura angularis) | STAGE III | STAGE III | STAGE IV | STAGE IV |
Sydney system for grading of chronic gastritis[1]
Sydney system for grading of Chronic Gastritis | ||
---|---|---|
Feature | Definition | Grading guidelines |
Chronic inflammation |
|
|
Activity |
|
|
Atrophy |
|
|
Helicobacter pylori |
|
|
Intestinal Metaplasia |
|
|
References
- ↑ 1.0 1.1 Dixon MF, Genta RM, Yardley JH, Correa P (1996). "Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994". Am J Surg Pathol. 20 (10): 1161–81. PMID 8827022.
- ↑ Rugge M, Meggio A, Pennelli G, Piscioli F, Giacomelli L, De Pretis G; et al. (2007). "Gastritis staging in clinical practice: the OLGA staging system". Gut. 56 (5): 631–6. doi:10.1136/gut.2006.106666. PMC 1942143. PMID 17142647.
- ↑ Rugge M, Correa P, Di Mario F, El-Omar E, Fiocca R, Geboes K; et al. (2008). "OLGA staging for gastritis: a tutorial". Dig Liver Dis. 40 (8): 650–8. doi:10.1016/j.dld.2008.02.030. PMID 18424244.